Theseus Pharmaceuticals IPO

Theseus Pharmaceuticals is committed to outsmarting cancer resistance by developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.

Register for Details

For more details on financing and valuation for Theseus Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Theseus Pharmaceuticals's ticker symbol?


What is Theseus Pharmaceuticals's stock price?

7.35 as of 3/27/23

Learn more about Theseus Pharmaceuticals

Forge green plus iconForge green minus icon

When was Theseus Pharmaceuticals founded?

Theseus Pharmaceuticals was founded in 2017.